For Patients

Our Melanoma Clinical Trial is Now Enrolling: NCT05470283

The University of Texas MD Anderson Cancer Center is currently enrolling patients in a Phase 1 clinical trial of OBX-115, which is being evaluated in patients with metastatic melanoma.

OBX-115 is an investigational cell therapy comprised of TILs genetically engineered to express membrane-bound IL15, a cytokine that is designed to remove the need for concomitant IL2 therapy, a toxic and costly requirement for conventional TILs.

One of the primary objectives of the Phase 1 clinical trial is to assess its safety, tolerability, and preliminary efficacy in patients with metastatic melanoma who have previously received other anti-cancer therapies.

Please contact clinical@obsidiantx.com for more information.

See Trial  

ABOUT OBX-115

OBX-115 is a novel engineered tumor-infiltrating lymphocyte (TIL) therapy armed with regulated membrane-bound IL15 that is designed to remove the need for concomitant IL2 therapy, a toxic and costly requirement for conventional TILs.

Preclinical data have demonstrated enhanced TIL persistence, potency and improved tumor control compared to unengineered TILs, which is anticipated to improve clinical outcomes in patients suffering from different types of solid tumors.

Benefits of TIL-endogenous mbIL15 vs. systemic IL2:

Drive antigen-independent
TIL expansion & persistence

Drive adjacent NK cell
expansion & activity

Drive phenotype towards
CD8+ and memory T-cells

Unlike IL2, suppresses activation-induced cell death, doesn’t expand immunosuppressive Tregs or cause capillary leak syndrome-associated toxicity

OBX-115 is developed without using IL2 in the rapid expansion phase
(REP) process, and designed to be used without concomitant IL2

Elimination of IL2 from the TIL treatment regimen is a significant advantage, driving the opportunity to displace un-engineered TIL therapy requiring systemic IL2. Systemic IL2 therapy is associated with serious side effects and is expensive and complicated to administer. Eliminating IL2 is projected to expand patient eligibility by enabling treatment of patients who cannot tolerate or access IL2 administration.

Our preclinical data across numerous in vitro and in vivo assays demonstrate enhanced potency, persistence, and anti-tumor efficacy of cytoTIL15™ (without IL2) compared to un-engineered TIL + IL2.

Our proprietary, differentiated manufacturing process drives a desired TIL phenotype (memory T-cells, CD8+ T cells) and generates less exhausted cells, which is anticipated to improve clinical outcomes in patients.

Our Pipeline Job Postings